Literature DB >> 17724810

Effect of preoperative transcatheter arterial chemoembolization on proliferation of hepatocellular carcinoma cells.

En-Hua Xiao1, Jing-Qing Li, Jie-Fu Huang.   

Abstract

AIM: To evaluate the effect of preoperative transcatheter arterial chemoembolization (TACE) on proliferation of hepatocellular carcinoma (HCC) cells.
METHODS: A total of 136 patients with HCC underwent liver resection. Of 136 patients, 79 patients received 1 to 5 courses of TACE prior to liver resection (TACE group), who were further subdivided into four groups: Group A (n = 11) who received 1 to 4 courses of chemotherapy alone; Group B (n = 33) who received 1 to 5 courses of chemotherapy combined with iodized oil; Group C (n = 23) who received 1 to 3 courses of chemotherapy combined with iodized oil and gelatin sponge; and Group D (n = 12) who received 1 to 3 courses of chemotherapy combined with iodized oil, ethanol and gelatin sponge. The other 57 patients only received liver resection (non-TACE group). The expressions of Ki-67 and proliferating cell nuclear antigen (PCNA) protein were detected in the liver cancer tissues by immunohistochemical method.
RESULTS: The Ki-67 protein expression was significantly lower in Groups C and D as compared with non-TACE group (31.35% +/- 10.85% vs 44.43% +/- 20.70%, 30.93% +/- 18.10% vs 44.43% +/- 20.70%, respectively, P < 0.05). The PCNA protein expression was significantly lower in Groups C and D as compared with non-TACE group (49.61% +/- 15.11% vs 62.92% +/- 17.21%, 41.16% +/- 11.83% vs 62.92% +/- 17.21%, respectively, P < 0.05). The Ki-67 protein expression was significantly higher in Group A as compared with non-TACE group (55.44% +/- 13.72% vs 44.43% +/- 20.70%, P < 0.05). The PCNA protein expression was significantly higher in Groups A and B as compared with non-TACE group (72.22% +/- 8.71% vs 62.92% +/- 17.21%, 69.91% +/- 13.38% vs 62.92% +/- 17.21%, respectively, P < 0.05).
CONCLUSION: Preoperative multi-material TACE suppresses the proliferation of HCC cells, while a single material embolization and chemotherapy alone enhance the proliferation of HCC cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724810      PMCID: PMC4611587          DOI: 10.3748/wjg.v13.i33.4509

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  14 in total

1.  Predictive value of Ki-67, p53 protein, and DNA content in the diagnosis of gastric carcinoma.

Authors:  N Igarashi; M Takahashi; H Ohkubo; K Omata; R Iida; S Fujimoto
Journal:  Cancer       Date:  1999-10-15       Impact factor: 6.860

2.  [The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma].

Authors:  Z Zhang; M Wu; Q Liu
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  1999-05

3.  Prognosis of primary liver carcinoma treated with local resection.

Authors:  Jianqiang Cai; Jingqun Hu; Xu Che; Jianjun Zhao; Xinyu Bi; Yongfu Shao
Journal:  Chin Med J (Engl)       Date:  2003-02       Impact factor: 2.628

4.  Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors.

Authors:  K Ueno; N Miyazono; H Inoue; H Nishida; I Kanetsuki; M Nakajo
Journal:  Cancer       Date:  2000-04-01       Impact factor: 6.860

5.  Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of nonsmall cell lung carcinoma with intrapulmonary metastases.

Authors:  T Fukuse; T Hirata; H Naiki; S Hitomi; H Wada
Journal:  Cancer       Date:  1999-10-01       Impact factor: 6.860

6.  [Pathomorphological study of resected hepatocellular carcinoma after transcatheter hepatic arterial chemo-embolization].

Authors:  R Q Lai
Journal:  Zhonghua Bing Li Xue Za Zhi       Date:  1993-02

7.  Transcatheter arterial chemoembolization as primary treatment for hepatocellular carcinoma.

Authors:  D M Rose; W C Chapman; A T Brockenbrough; J K Wright; A T Rose; S Meranze; M Mazer; T Blair; C D Blanke; J P Debelak; C W Pinson
Journal:  Am J Surg       Date:  1999-05       Impact factor: 2.565

8.  Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. An analysis of DNA content (ploidy), cellular proliferation, and p53 expression.

Authors:  A Perry; R B Jenkins; J R O'Fallon; P L Schaefer; D W Kimmel; M R Mahoney; B W Scheithauer; S M Smith; E M Hill; T J Sebo; R Levitt; J Krook; L K Tschetter; R F Morton; J C Buckner
Journal:  Cancer       Date:  1999-08-15       Impact factor: 6.860

9.  Prognostic histologic features of resected small hepatocellular carcinoma (HCC) in Taiwan. A comparison with resected large HCC.

Authors:  H C Hsu; J C Sheu; Y H Lin; D S Chen; C S Lee; L Y Hwang; R P Beasley
Journal:  Cancer       Date:  1985-08-01       Impact factor: 6.860

10.  Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization.

Authors:  En-Hua Xiao; Jing-Qing Li; Jie-Fu Huang
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

View more
  3 in total

1.  Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells.

Authors:  En-Hua Xiao; Dong Guo; Du-Jun Bian
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

Review 2.  Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies.

Authors:  Danielle L Stolley; Anna Colleen Crouch; Aliçan Özkan; Erin H Seeley; Elizabeth M Whitley; Marissa Nichole Rylander; Erik N K Cressman
Journal:  Pharmaceutics       Date:  2020-12-20       Impact factor: 6.321

3.  Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: A biopsy and resection matched study.

Authors:  Ji Hae Nahm; Hyungjin Rhee; Haeryoung Kim; Jeong Eun Yoo; Jee San Lee; Youngsic Jeon; Gi Hong Choi; Young Nyun Park
Journal:  Oncotarget       Date:  2017-10-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.